Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
University of Oklahoma
Study ID
NCT07737795
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • OK-1 & Paclitaxel — DRUG
    OK-1 capsules will be administered orally at 3.5-4.5 mg/kg twice a day during a 21-day cycle (3 weeks on, one week off in a 28-day cycle) Other Names: • NSC 726189 Paclitaxel will be administered 60-70 mg/m2 IV on Day 1,8 and 15 (3 weeks on, one week off in a 28-day cycle)

Study Details

The purpose of this study is to evaluate whether treatment with the investigational drug OK-1 in combination with paclitaxel can reduce tumor burden in patients with advanced or recurrent endometrial cancer (A/R-EC).

Key Dates

First listed
Jul 30, 2026
Start date
Aug 31, 2026
Status verified
Jul 2026
Primary completion
Aug 31, 2028
Completion
Aug 31, 2029

Study Design

Enrollment
66 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 2 Cohort
    OK-1 (oral, BID) 28-days cycle. Weekly Paclitaxel (IV) 21-days cycle.

Primary Outcome Measure

Number and Proportion of Patients Who Safely Tolerate The Combination of OK-1 and Paclitaxel [ Time Frame: 12 Months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
OU Health Stephenson Cancer CenterOklahoma CityOklahoma73117
Kathleen Moore, MD
[email protected]

Find similar trials in Oklahoma City, OK

Nationwide
Endometrial cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials
By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
OU Health Stephenson Cancer Center· Oklahoma City, OK

Related Studies